MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- 13 February 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (3), 249-256
- https://doi.org/10.1016/s1470-2045(13)70024-x
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorJournal of Clinical Oncology, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced MelanomaClinical Cancer Research, 2012
- Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced MelanomaJournal of Immunotherapy, 2012
- Aberrant B-Raf Signaling in Human Cancer - 10 Years from Bench to BedsideCritical Reviews™ in Oncogenesis, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- MEK1 mutations confer resistance to MEK and B-RAF inhibitionProceedings of the National Academy of Sciences of the United States of America, 2009
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005